XENE — Xenon Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1582313 ·
British Columbia, Canada
Last close
$36.16
Market Cap
$3.50B
52W High
$72.66
52W Low
$35.06
ADV30
2,159,058
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -123,155,000 | -110,736,000 | 1,295,772,000 | 119,527,000 | 53,376,000 |
| Mar 2026 | 0 | — | -112,328,000 | -102,302,000 | 1,386,810,000 | 545,867,000 | 48,991,000 |
| Dec 2025 | 0 | — | -109,767,000 | -105,261,000 | 633,163,000 | 199,163,000 | 51,403,000 |
| Sep 2025 | 0 | — | -96,336,000 | -90,896,000 | 607,836,000 | 104,514,000 | 48,325,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-306,363,000
Investing CF
$-223,794,000
Financing CF
$958,975,000
CapEx
$-889,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.70
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,347,682,000
Inventory
—
Receivables
$1,165,000
ST Investments
$548,880,000
EBIT TTM
$-412,660,000
Pretax Income TTM
$-385,147,000
Interest Exp TTM
—
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-439,188,992
Free Cash Flow
$-203,547,248
Enterprise Value
$4,755,423,232
Total Cash
$930,686,016
Total Debt
$6,418,000
Shares Out
96,840,432
Trailing EPS
$-4.74
Book Value
$12.84
ROE
-43.6%
ROA
-28.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,500,000 | -373,070,000 | -345,910,000 | 633,163,000 | 51,403,000 | 581,760,000 | -279,118,000 |
| Dec 2024 | 0 | -279,298,000 | -234,330,000 | 798,139,000 | 43,236,000 | 754,903,000 | -181,389,000 |
| Dec 2023 | 0 | -214,054,000 | -182,393,000 | 964,798,000 | 36,877,000 | 927,921,000 | -151,112,000 |
| Dec 2022 | 9,434,000 | -129,143,000 | -125,373,000 | 754,146,000 | 32,649,000 | 721,497,000 | -101,028,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-383,165,000
OpCashFlow TTM
—
Assets (Latest)
$1,386,810,000
Forward EPS
$-4.80
Max Pain — expiry 2026-10-16
max pain strike: $40.00 · spot: $36.44 · call oi: 4,409 · put oi: 1,125
Expected Move to 2026-10-16:
±$2.23
(6.11%) —
implied range
$34.21 –
$38.66
· ATM straddle on $37.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | $3.48B | $36.06 | — |
| PBLS | Parabilis Medicines, Inc. | $3.43B | $28.09 | — |
| OGN | Organon & Co. | $3.61B | $13.75 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.37B | $19.58 | — |
| LEGN | Legend Biotech Corp | $3.64B | $18.71 | — |
News headlines (Yahoo Finance, 1h cache)
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
2026-10-09 14:14 · Yahoo
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:01 · Yahoo
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
2026-10-01 16:10 · Yahoo
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
2026-10-01 15:02 · Yahoo
Ian Mortimer Receives the 2026 Bloom Burton Award
2026-09-29 12:00 · Yahoo
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
2026-09-27 16:02 · Yahoo
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
2026-09-23 00:08 · Yahoo
Xenon stock lost 30%, but the FDA story is more complicated
2026-09-22 00:03 · Yahoo
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
2026-09-21 20:01 · Yahoo
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment
2026-09-21 11:37 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-01 9:20:20 | 2026-09-30 | Kelly Thomas Patrick | CFO | P - Purchase | 37.32 | 15000 | 559740 |
| 2026-10-01 9:19:28 | 2026-09-30 | Mortimer Ian | Pres, CEO | P - Purchase | 37.38 | 30000 | 1121400 |